Innovent Biologics, Inc.
IVBXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$161.3B
Close$
Share Statistics
| Market cap | $161.30 Billion |
|---|---|
| Enterprise Value | $148.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.47 |
| Beta | 0.24 |
| Outstanding Shares | 1,726,008,719 |
Return
| Return on Equity | 11.32% |
|---|---|
| Return on Assets | 5.64% |
| Return on Invested Capital | 7.10% |
Valuation & Multiples
| P/E Ratio | 111.42 |
|---|---|
| PEG | 231.51 |
| Price to Sales | 0.81 |
| Price to Book Ratio | 1.01 |
| Enterprise Value to Revenue | 5.49 |
| Enterprise Value to EBIT | 64.71 |
| Enterprise Value to Net Income | 63 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$1.31 B
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$1.51 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Innovent Biologics, Inc.
8,754 employees
CEO: De-Chao Yu Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidat...